Pulmonx Corporation
LUNG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $266 | $484 | $313 | $1,159 |
| - Cash | $71 | $84 | $102 | $148 |
| + Debt | $56 | $41 | $24 | $26 |
| Enterprise Value | $251 | $442 | $235 | $1,037 |
| Revenue | $84 | $69 | $54 | $48 |
| % Growth | 22% | 28% | 10.8% | – |
| Gross Profit | $62 | $51 | $40 | $36 |
| % Margin | 74% | 73.9% | 74.3% | 73.6% |
| EBITDA | -$51 | -$55 | -$56 | -$47 |
| % Margin | -60.6% | -80.2% | -104.3% | -96.3% |
| Net Income | -$56 | -$61 | -$59 | -$49 |
| % Margin | -67.3% | -88.6% | -109.8% | -100.5% |
| EPS Diluted | -1.44 | -1.6 | -1.59 | -1.35 |
| % Growth | 10% | -0.6% | -17.8% | – |
| Operating Cash Flow | -$32 | -$38 | -$45 | -$41 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$4 |
| Free Cash Flow | -$33 | -$38 | -$46 | -$45 |